title: Clinical and echographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinant factor VIIa in the evolution process (EFFISEVEN protocol).
abstract: The intention of the 'clinical and echographical protocol of evaluation the efficacy of recombinant activated factor VII in the haemarthrosis' (EFFISEVEN protocol) was to provide an extensive study of the evolution of haemarthrosis, and second, of its repercussions on the degenerative process of joints. The clinical evaluation of haemarthroses and their evolution is based on a well-established methodology, although very few studies have sought to determine the correlation between pain, mobility and the objective data regarding the haemorrhage. We believe that it is necessary to unify criteria and that the EFFISEVEN protocol may contribute data that improve standards which, in turn, will influence the degenerative process of joints, and consequently affect the quality of life of haemophilia patients with inhibitors. Echographical control of haemarthrosis is an objective method that allows control over how the haemorrhage evolves and also helps in the identification of rebleeding. Therefore, its use adds a new dimension to patient management strategies. Techniques used to monitor recombinant activated factor VII (rFVIIa) treatment require further study, although preliminary results guarantee their efficacy.
authors.affiliation: Unidad de Coagulopatías del Hospital Universitario La Fe, Valencia, Spain. querol@uv.es
authors.forename: F
authors.initials: F
authors.lastname: Querol
authors.forename: V
authors.initials: V
authors.lastname: Cortina
authors.forename: A R
authors.initials: AR
authors.lastname: Cid
authors.forename: S
authors.initials: S
authors.lastname: Haya
authors.forename: J A
authors.initials: JA
authors.lastname: Aznar
mesh_terms: D000293:Adolescent; D000328:Adult; D018771:Arthralgia / Q000209:etiology; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood; D001779:Blood Coagulation Factors / Q000378:metabolism / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D002985:Clinical Protocols; D004334:Drug Administration Schedule; D005060:Europe; D015942:Factor VIIa / Q000378:metabolism / Q000627:therapeutic use*; D006395:Hemarthrosis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D006467:Hemophilia A / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D011788:Quality of Life; D016059:Range of Motion, Articular / Q000187:drug effects; D011994:Recombinant Proteins / Q000378:metabolism / Q000627:therapeutic use; D013997:Time Factors; D014463:Ultrasonography; D055815:Young Adult
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa